Metformin as adjuvant in standard therapy in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis
South Asian Journal of Cancer · 18.05.2026 · 15 · 143-150
DOI: 10.25259/sajc_11_2025 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift South Asian Journal of Cancer, online erschienen am 18.05.2026. Verfasst von Muhammad Bimo Ramadhan und 3 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Diffuse large B-cell lymphoma (DLBCL) is the leading form of adult non-Hodgkin lymphoma (NHL), accounting for 4–5% of new cancer diagnoses and 3–4% of cancer-related mortalities. Preliminary studies on the addition of metformin to chemotherapy have resulted in higher survival and response rates, but the results found still vary. Since no meta-analysis has been published examining this topic, our study investigates the efficacy of metformin as an adjuvant in DLBCL by measuring Overall Survival (OS), Event-Free Survival (EFS), and Objective Response Rate (ORR). Material and Methods: Literature retrieval included searches in four main databases, including PubMed, Scopus, Cochrane, and ClinicalTrials.gov, from all publication years. The search keywords included “Metformin,” “DLBCL,” “Adjuvant therapy,” and “Diabetes Mellitus”. PRISMA checklist was used to select articles to ensure a comprehensive review. The quality of each article was critically reviewed using the Cochrane RoB 2 tools for RCTs or ROBINS-I for non-randomised studies.
Results
From the search results, 7 studies were identified (n = 1344). OS and EFS were found to be significantly better in the metformin group compared to the control group, with a hazard ratio (HR) of 0.54 [0.34–0.87] and 0.54 [0.36–0.82], respectively; while ORR was found to be non-significant (RR: 1.16 [0.98–1.38]). Subgroup analysis for studies with diabetic populations showed similar significant effects on OS and EFS, with HR of 0.54 [0.33–0.88] and 0.56 [0.40–0.77], respectively. Meta-regression results indicate greater therapeutic effect (lower OS and EFS hazard ratio) in lower risk patients (International Prognostic Index (IPI) score 0–2).
Conclusion
Metformin as adjuvant therapy in DLBCL patients has demonstrated a trend in reducing mortality and disease progression, more effectively in lower-risk patients (IPI score 0–2). To further elaborate on the beneficial effects of metformin, a prospective, randomised, double-blinded study with a larger population is warranted, specifically targeting the low-risk DLBCL patients.
Zitieren
APA
Ramadhan, M. B., Hakim, M. H., Suskhan, M. N., & Cahyanur, R. (2026). Metformin as adjuvant in standard therapy in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis. South Asian Journal of Cancer, 15, 143-150. https://doi.org/10.25259/sajc_11_2025
Vancouver
Ramadhan MB, Hakim MH, Suskhan MN, Cahyanur R. Metformin as adjuvant in standard therapy in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis. South Asian Journal of Cancer. 2026;15:143-150. doi:10.25259/sajc_11_2025
BibTeX
@article{Ramadhan2026,
author = {Ramadhan, Muhammad Bimo and Hakim, Muhammad Hatta and Suskhan, Mutiara Nurlena and Cahyanur, Rahmat},
title = {Metformin as adjuvant in standard therapy in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis},
journal = {South Asian Journal of Cancer},
year = {2026},
volume = {15},
pages = {143--150},
doi = {10.25259/sajc_11_2025}
}
EUVIMED